Children's Mercy Expands Cell and Gene Therapy Program with Basepath Health Partnership

Children's Mercy has announced a major expansion of its cell and gene therapy program in collaboration with Basepath Health, according to a press release. The partnership will combine clinical expertise with Basepath's AI supported operating platform to improve the delivery of advanced therapies for children with rare and complex conditions.

The expansion will increase Children's Mercy's capacity to deliver cell and gene therapies and shorten the time patients wait for treatment. The health system will oversee clinical care, while Basepath Health will provide an operating model that coordinates pre treatment, treatment, and post treatment workflows, including patient identification, education, and long term outcomes tracking.

Children's Mercy currently offers several FDA approved therapies, such as Zolgensma, Itvisma, Elevidys, Casgevy, and Kymriah. The program aims to treat five times as many patients within four years by scaling access to new therapies as they become available.

Basepath Health’s platform is designed to reduce administrative workload for clinical teams, allowing physicians and caregivers to focus on patient care. The collaboration seeks to make advanced treatments more accessible within a dedicated pediatric environment.